Altimmune Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Altimmune Inc Unternehmen

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.

Altimmune Inc Informationen



BörsenkürzelALT

Name des UnternehmensAltimmune Inc

IPO-datumOct 06, 2005

CEODr. Vipin K. Garg, Ph.D.

Anzahl der mitarbeiter59

WertpapierartOrdinary Share

GeschäftsjahresendeOct 06

Addresse910 Clopper Road

StadtGAITHERSBURG

BörseNASDAQ Global Market Consolidated

LandUnited States of America

Postleitzahl20878-1361

Telefon12406541450

Websitehttps://altimmune.com/

BörsenkürzelALT

IPO-datumOct 06, 2005

CEODr. Vipin K. Garg, Ph.D.

Führungskräfte von Altimmune Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Vipin K. Garg, Ph.D.

President, Chief Executive Officer, Director

355.08K

--

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

36.27K

+3.92%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

--

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

10.00K

--

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

--

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.00K

--

Ms. Linda M. Richardson

Chief Commercial Officer

--

Mr. Philip L. Hodges

Independent Director

--

Mr. Jerome Benedict (Jerry) Durso

Chairman of the Board

--

Dr. M. Scot Roberts, Ph.D.

Chief Scientific Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Vipin K. Garg, Ph.D.

President, Chief Executive Officer, Director

355.08K

--

Mr. Raymond M. (Ray) Jordt

Chief Business Officer

36.27K

+3.92%

Dr. Mitchel B. (Mitch) Sayare, Ph.D.

Independent Director

26.36K

--

Mr. Gregory L. (Greg) Weaver

Chief Financial Officer

10.00K

--

Brig. Gen. (Retd.) Klaus O. Schafer, M.D.

Independent Director

9.18K

--

Dr. Catherine Angell Sohn, Pharm.D.

Independent Director

1.00K

--

Umsatzaufteilung

Keine Daten

Keine Daten

Nach Geschäftsbereich

Nach Region

Keine Daten

Aktionärsstatistik

Aktualisiert: Tue, Nov 4

Aktionäre

Aktionärstypen

Aktionäre

Anteil

The Vanguard Group, Inc.

6.11%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

2.64%

Tang Capital Management, LLC

2.64%

Geode Capital Management, L.L.C.

1.86%

Andere

81.23%

Aktionäre

Anteil

The Vanguard Group, Inc.

6.11%

BlackRock Institutional Trust Company, N.A.

5.52%

State Street Investment Management (US)

2.64%

Tang Capital Management, LLC

2.64%

Geode Capital Management, L.L.C.

1.86%

Andere

81.23%

Aktionärstypen

Aktionäre

Anteil

Investment Advisor

20.68%

Investment Advisor/Hedge Fund

9.49%

Hedge Fund

7.78%

Research Firm

3.16%

Individual Investor

0.73%

Bank and Trust

0.38%

Pension Fund

0.05%

Insurance Company

0.03%

Andere

57.70%

Institutionelle Beteiligung



Aktualisiert: Wed, Oct 1

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q3

405

38.06M

36.57%

-11.64M

2025Q2

413

40.03M

49.36%

-12.37M

2025Q1

433

39.51M

48.72%

-15.43M

2024Q4

439

41.91M

54.50%

-15.25M

2024Q3

440

40.83M

57.43%

-21.59M

2024Q2

436

43.67M

61.47%

-20.29M

2024Q1

418

45.76M

64.68%

-11.45M

2023Q4

387

34.44M

49.06%

-14.90M

2023Q3

368

31.34M

59.36%

-25.59M

2023Q2

362

36.16M

68.78%

-25.80M

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

The Vanguard Group, Inc.

5.17M

5.85%

+772.36K

+17.57%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.75M

6.52%

+223.90K

+4.05%

Jun 30, 2025

State Street Investment Management (US)

2.75M

3.12%

-637.93K

-18.81%

Jun 30, 2025

Tang Capital Management, LLC

2.75M

3.12%

--

Jun 30, 2025

Geode Capital Management, L.L.C.

1.93M

2.19%

+229.00K

+13.42%

Jun 30, 2025

Susquehanna International Group, LLP

1.62M

1.84%

+543.68K

+50.53%

Jun 30, 2025

Knoll Capital Management, LLC

1.12M

1.27%

--

Jun 30, 2025

Caption Management, LLC

980.78K

1.11%

+941.92K

+2423.62%

Jun 30, 2025

BofA Global Research (US)

716.02K

0.81%

+435.47K

+155.22%

Jun 30, 2025

UBS Financial Services, Inc.

633.56K

0.72%

-94.60K

-12.99%

Jun 30, 2025

Verbundene ETFs



Aktualisiert: Thu, Nov 6

Name

Anteil

Invesco NASDAQ Future Gen 200 ETF

0.48%

Virtus LifeSci Biotech Clinical Trials ETF

0.38%

SPDR S&P Biotech ETF

0.15%

Direxion Daily S&P Biotech Bull 3X Shares

0.08%

Fidelity Enhanced Small Cap ETF

0.06%

iShares Micro-Cap ETF

0.06%

iShares Biotechnology ETF

0.03%

Invesco Nasdaq Biotechnology ETF

0.03%

ProShares Ultra Nasdaq Biotechnology

0.03%

iShares Russell 2000 Growth ETF

0.02%

Invesco NASDAQ Future Gen 200 ETF

Anteil0.48%

Virtus LifeSci Biotech Clinical Trials ETF

Anteil0.38%

SPDR S&P Biotech ETF

Anteil0.15%

Direxion Daily S&P Biotech Bull 3X Shares

Anteil0.08%

Fidelity Enhanced Small Cap ETF

Anteil0.06%

iShares Micro-Cap ETF

Anteil0.06%

iShares Biotechnology ETF

Anteil0.03%

Invesco Nasdaq Biotechnology ETF

Anteil0.03%

ProShares Ultra Nasdaq Biotechnology

Anteil0.03%

iShares Russell 2000 Growth ETF

Anteil0.02%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Art

Verhältnis

Keine Daten

Datum

Art

Verhältnis

Keine Daten